FOLH1 and posterior cortical atrophy: In parallel, a recently opened phase I/2 trial (LuCAB, NCT05340374) will assess the safety and efficacy of cabazitaxel in combination with [177Lu]Lu-PSMA-617 in PCa patients [236].